OverviewSuggest Edit

The Nurix scientific team has established an innovative drug discovery platform based on recent advances in understanding of the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls protein homeostasis, the stabilization and degradation of cellular proteins. This process is vital to the healthy life of a cell and provides opportunities to discover new drugs in multiple disease areas. Nurix’s Protein Regulation Platform enables the discovery of selective inhibitors or activators of the UPS, enabling the development of new class of drugs. In September 2015, Nurix entered into an exclusive collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis in oncology, immunology and inflammation, including the rapidly evolving field of immuno-oncology. Nurix was founded by internationally-recognized experts in the ubiquitin proteasome field and is funded by leading life science investors Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California.
TypePrivate
Founded2009
HQSan Francisco, US
Websitenurixtx.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Sept 2020)125(+4%)
Cybersecurity ratingAMore

Key People/Management at Nurix

Arthur T. Sands

Arthur T. Sands

Chief Executive Officer and Director
David Lacey

David Lacey

Chairman
Leon Chen

Leon Chen

Director
Gwenn Hansen

Gwenn Hansen

Chief Scientific Officer
Jeff Tong

Jeff Tong

Director
Julia Gregory

Julia Gregory

Director
Show more

Nurix Office Locations

Nurix has an office in San Francisco
San Francisco, US (HQ)
1700 Owens St #205, San Francisco
Show all (1)

Nurix Financials and Metrics

Summary Metrics

Founding Date

2009

Nurix total Funding

$165.2 m

Nurix latest funding size

$120 m

Time since last funding

6 months ago

Nurix investors

Nurix's latest funding round in March 2020 was reported to be $120 m. In total, Nurix has raised $165.2 m
Show all financial metrics

Nurix Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Nurix Online and Social Media Presence

Embed Graph

Nurix News and Updates

Nurix Therapeutics shares slide 2.3% in trading debut

Nurix Therapeutics Inc. shares fell 2.3% in their trading debut Friday, after pricing above the proposed price range. Nurix sold 11 million shares priced at $19 each, above a recently tweaked $17 to $18 range. Its original plan was to sell 8.8 million shares priced at $16 to $18. The shares are tra…

Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering

SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nurix), a company developing targeted protein modulation drugs, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the sh…

Biotech Nurix Therapeutics to offer 11 million shares in planned IPO, priced at $17 to $18 each

Nurix Therapeutics Inc. set terms for its initial public offering on Thursday, with plans to offer 11 million shares priced at $17 to $18 each. The company has applied to list on Nasdaq, under the ticker "NRIX." JPMorgan, Piper Sandler, Stifel and Needham & Co. are underwriting the deal. Procee…

Nurix Therapeutics sets IPO terms, to be valued at up to $627 million

Nurix Therapeutics Inc. disclosed Monday the terms for its initial public offering, in which the San Francisco-based biopharmaceutical company focused on cancer treatments could raise up to $158.4 million and be valued at as much as $627.1 million. The company is offering 8.8 million shares for sa…

Gilead strikes deal with Nurix Therapeutics to tackle disease-causing proteins

Gilead Sciences Inc. is partnering with Nurix Therapeutics, a biotech working on drugs to destroy disease-causing proteins, the companies announced Wednesday. Under the terms of the multi-year deal, Gilead will have the option to license certain drug candidates from Nurix, and Nurix will have the …

Nurix Blogs

Scientist (Senior Sci to Principal Sci), Medicinal Chemistry

We are seeking a curious and motivated individual to join the Medicinal Chemistry group. This individual will drive the chemistry effort to enable novel ligases for targeted protein degradation. With a strong background in synthetic organic chemistry, the successful candidate will have experience in…

Scientist/Sr. Scientist, DNA Encoded Chemistry, Library Discovery

Nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. Nurix is a leader in discovering a new class of drugs that work by modulating E3 ubiquitin ligases within the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls…

Associate Director/Director, Clinical Data Management

Nurix was founded by internationally recognized experts in the ubiquitin-proteasome (UPS) field and received its initial funding from leading life science investors Third Rock Ventures and The Column Group.  Nurix recently entered into a multi-year collaboration with Gilead and Sanofi focused on dev…

Informatics Scientist

As an Informatics Scientist, you will interface with fellow scientists across Research and Development to provide hands-on scientific application support.  In this role, you will help fellow scientists effectively use Nurix’s tools and applications to capture, analyze, query and report R&D data …

Scientist I, Medicinal Chemistry

We are seeking a talented and highly motivated chemist with a strong background in synthetic organic chemistry to join our Medicinal Chemistry team. You will work with a highly dynamic group that is focused on moving projects from the hit identification stage to the discovery of clinical candidates.…

Director/Senior Director, Clinical Scientist

Nurix has a place for an extraordinary, highly motivated, and accomplished Director/Senior Director, Clinical Scientist. As an integral member of the Clinical Development Team, this person will help to develop innovative solutions for the clinical development of Nurix’s pioneering protein modulation…
Show more

Nurix Frequently Asked Questions

  • When was Nurix founded?

    Nurix was founded in 2009.

  • Who are Nurix key executives?

    Nurix's key executives are Arthur T. Sands, David Lacey and Leon Chen.

  • How many employees does Nurix have?

    Nurix has 125 employees.

  • Who are Nurix competitors?

    Competitors of Nurix include Clementia Pharmaceuticals, DBV Technologies and Cord Blood America.

  • Where is Nurix headquarters?

    Nurix headquarters is located at 1700 Owens St #205, San Francisco, San Francisco.

  • Where are Nurix offices?

    Nurix has an office in San Francisco.

  • How many offices does Nurix have?

    Nurix has 1 office.